EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1

Muhammad Saqib Sohail iD, Syed Faraz Ahmed iD, Ahmed Abdul Quadeer iD, Matthew R McKay iD

Viruses · 2024

DOI: 10.3390/v16030473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Muhammad Saqib Sohail und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Theme-Based Research Scheme of the Hong Kong Research Grants Council (RGC), Australian Research Council (ARC) Discovery Project, ARC Future Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS-CoV-2 Omicron sub-variants BA.2.86 and JN.1 contain multiple mutations in the spike protein that were not present in previous variants of concern and Omicron sub-variants. Preliminary research suggests that these variants reduce the neutralizing capability of antibodies induced by vaccines, which is particularly significant for JN.1. This raises concern as many widely deployed COVID-19 vaccines are based on the spike protein of the ancestral Wuhan strain of SARS-CoV-2. While T cell responses have been shown to be robust against previous SARS-CoV-2 variants, less is known about the impact of mutations in BA.2.86 and JN.1 on T cell responses. We evaluate the effect of mutations specific to BA.2.86 and JN.1 on experimentally determined T cell epitopes derived from the spike protein of the ancestral Wuhan strain and the spike protein of the XBB.1.5 strain that has been recommended as a booster vaccine. Our data suggest that BA.2.86 and JN.1 affect numerous T cell epitopes in spike compared to previous variants; however, the widespread loss of T cell recognition against these variants is unlikely.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesHumansCOVID-19 VaccinesEpitopes, T-LymphocyteSARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesAntibodies, NeutralizingAntibodies, Viral

Stichwörter der Autor:innen

BA.2.86COVID-19JN.1SARS-CoV-2T cell epitopesimmune escapemutationsvaccines

Substanzen

COVID-19 VaccinesEpitopes, T-LymphocyteSpike Glycoprotein, CoronavirusVaccinesAntibodies, NeutralizingAntibodies, Viralspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
  • Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.
  • Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.

ORCID-Profile: Muhammad Saqib Sohail, Syed Faraz Ahmed, Ahmed Abdul Quadeer, Matthew R McKay

Förderung

  • Theme-Based Research Scheme of the Hong Kong Research Grants Council (RGC)
  • Australian Research Council (ARC) Discovery Project
  • ARC Future Fellowship
  • Hong Kong Research Grants Council (RGC)
  • Australian Research Council (ARC)

Zitieren

APA

Sohail, M. S., Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2024). Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1. Viruses. https://doi.org/10.3390/v16030473

Vancouver

Sohail MS, Ahmed SF, Quadeer AA, McKay MR. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1. Viruses. 2024. doi:10.3390/v16030473

BibTeX
@article{Sohail2024,
  author = {Sohail, Muhammad Saqib and Ahmed, Syed Faraz and Quadeer, Ahmed Abdul and McKay, Matthew R},
  title = {Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16030473}
}
Kostenlos starten →